Comparison of the efficacy of Ticagrelor and Clopidogrel in the treatment of acute ST-segment elevation myocardial infarction before percutaneous coronary intervention
LI Peng XU Jianhui HU Wei
The Second Department of Cardiology,Xiaogan Hospital Affiliated to Wuhan University of Science and Technology(Xiaogan Central Hospital),Hubei Province,Xiaogan 432000,China
Abstract:Objective To compare the efficacy of ticagrelor and Clopidogrel in the treatment of acute ST-segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention. Methods A total of 112 STEMI patients who received percutaneous coronary intervention (PCI) treatment in Xiaogan Hospital Affiliated to Wuhan University of Science and Technology from January 2015 to February 2019 were selected as research objects,and they were divided into Ticagrelor group and Clopidogrel group according to random number table method,with 56 cases in each group. Ticagrelor group was given Ticagrelor Tablets before PCI,and Clopidogrel group was given Clopidogrel Bisulfate Tablets before PCI. The changes of PCI indexes,myocardial enzymology indexes and N-terminal B-type brain natriuretic peptide precursor (NT-proBNP) level 24 h after operation were compared between the two groups. The incidence of adverse cardiovascular events in the two groups was calculated after 6 months follow-up. Results TIMI blood flow grading in Ticagrelor group was better than that in Clopidogrel group,the incidence of coronary chronic blood flow was lower than that in Clopidogrel group,and the differences were statistically significant (P<0.05). Troponin I,phosphocatine kinase isoenzyme and NT-proBNP 24 h after surgery in the two groups were lower than those before treatment,and the troponin I,phosphocatine kinase isoenzyme and NT-proBNP in Ticagrelor group were lower than those in Clopidogrel group,the differences were statistically significant (P<0.05). After 6 months of follow-up,the total incidence of adverse cardiovascular events in Ticagrelor group was lower than that in Clopidogrel group,and the difference was statistically significant (P<0.05). Conclusion Compared with clopidogrel,the application of tigrelor before PCI can better restore coronary blood supply,reduce the incidence of chronic coronary blood flow,reduce myocardial injury,and have a clear effect of reducing the risk of adverse cardiovascular events.
李朋;徐建辉;胡威. 经皮冠脉介入术前应用替格瑞洛与氯吡格雷治疗急性ST段抬高型心肌梗死的效果比较[J]. 中国当代医药, 2022, 29(1): 76-79.
LI Peng XU Jianhui HU Wei. Comparison of the efficacy of Ticagrelor and Clopidogrel in the treatment of acute ST-segment elevation myocardial infarction before percutaneous coronary intervention. 中国当代医药, 2022, 29(1): 76-79.
Meneveau N,Souteyrand G,Motreff P,et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: Results of the multicenter,randomized DOCTORS study (Does Optical Coherence Tomography Optimize Results of Stenting) [J].Circulation,2016,134(13):906-917.
Park KH,Jeong MH,Ahn Y,et al.Comparison ofshort-term clinical outcomes between ticagrelor versusclopidogrel in patients with acute myocardial infarctionundergoing successful revascularization;from KoreaAcute Myocardial Infarction Registry-National Institute of Health[J].Int J Cardiol,2016,215:193-200.
[14]
Andreotti F,Rocca B,Husted S,et al.Antithrombotictherapy in the elderly:expert position paper of the European Society of Cardiology Working Group on Thrombosis[J].Eur Heart J,2015,36(46):3238-3249.